BILTHOVEN, The Netherlands, June 30, 2023 — Bilthoven Biologicals (BBio) today announced that it is one of the selected companies in Europe to be granted a pandemic preparedness contract by the European Commission. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of viral vector vaccines in emergency situations in Europe.

The Serum Institute of India Pvt., Ltd., the Supervisory Board and CEO of Bilthoven Biologicals B.V. have agreed that the CEO steps down as Managing Director on March 31st, 2023.

In November 2022, a Bilthoven Biologicals employee became infected with the polio virus during his work. The company then ceased activities with active polio virus. An investigation into the cause and improvement actions were successfully carried out. On February 6, the company will restart production of polio vaccines.